PrEP Scale-Up and PEP in Central and Eastern Europe: Changes in Time and the Challenges We Face with No Expected HIV Vaccine in the near Future

Author:

Gokengin Deniz12ORCID,Bursa Dominik3,Skrzat-Klapaczynska Agata3,Alexiev Ivailo4ORCID,Arsikj Elena5ORCID,Balayan Tatevik6,Begovac Josip7ORCID,Cicic Alma8,Dragovic Gordana9,Harxhi Arjan10,Aimla Kerstin11,Lakatos Botond12,Matulionyte Raimonda13,Mulabdic Velida14,Oprea Cristiana15,Papadopoulos Antonios16ORCID,Rukhadze Nino17ORCID,Sedlacek Dalibor18ORCID,Sojak Lubomir19ORCID,Tomazic Janez20,Vassilenko Anna21ORCID,Vasylyev Marta2223,Verhaz Antonija24,Yancheva Nina25,Yurin Oleg26ORCID,Kowalska Justyna327

Affiliation:

1. Department of Infectious Diseases and Clinical Microbiology, Medical Faculty, Ege University, Izmir 35100, Türkiye

2. HIV/AIDS Research and Practice Center, Ege University, Izmir 35100, Türkiye

3. Department of Adults’ Infectious Diseases, Hospital for Infectious Diseases, Medical University of Warsaw, 01-201 Warsaw, Poland

4. Department of Virology, National Center of Infectious and Parasitic Diseases, 1504 Sofia, Bulgaria

5. University Clinic for Infectious Diseases and Febrile Conditions Skopje, Faculty of Medicine Skopje, Ss.Cyril and Methodius University, 1010 Skopje, North Macedonia

6. National Center for Disease Control and Prevention, Yerevan 0025, Armenia

7. Department of Infectious Diseases, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia

8. Center for Communicable Disease Control and Prevention, Institute for Public Health of Montenegro, 81000 Podgorica, Montenegro

9. Department of Pharmacology, Clinical Pharmacology and Toxicology, School of Medicine, University of Belgrade, 11000 Belgrade, Serbia

10. Department of Infectious Disease, Faculty of Medicine, University Hospital Center of Tirana, 1001 Tirana, Albania

11. Department of Infectious Diseases, Tartu University Hospital, 50406 Tartu, Estonia

12. Department of HIV and Tropical Diseases, South Pest Central Hospital, National Institute of Hematology and Infectious Diseases, 1097 Budapest, Hungary

13. Department of Infectious Diseases and Dermatovenerology, Vilnius University Hospital Santaros Klinikos, Vilnius University, LT-08410 Vilnius, Lithuania

14. Clinic for Infectious Diseases, Clinical Center University of Sarajevo, 71000 Sarajevo, Bosnia and Herzegovina

15. Victor Babes Hospital for Infectious and Tropical Diseases, Carol Davila University of Medicine and Pharmacy, 030303 Bucharest, Romania

16. 4th Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, University General Hospital “ATTIKON”, 12462 Athens, Greece

17. Infectious Diseases, AIDS & Clinical Immunology Research Center, 0160 Tbilisi, Georgia

18. HIV Center University Hospital, Charles University, 11000 Pilsen, Czech Republic

19. Center for Treatment of HIV/AIDS Patients, Department of Infectology and Geographical Medicine, Academic L. Derer’s University Hospital, 2412 Bratislava, Slovakia

20. Department of Infectious Diseases, University Medical Center Ljubljana, 1525 Ljubljana, Slovenia

21. Global Fund Grant Management Department, Republican Scientific and Practical Center of Medical Technologies, Informatization, Management and Economics of Public Health (RNPT MT), 220013 Minsk, Belarus

22. Astar Medical Center, 79054 Lviv, Ukraine

23. Internal Medicine Department, Erasmus MC, 2040 3000 Rotterdam, The Netherlands

24. Clinic for Infectious Diseases, University Clinical Center of the Republic of Srpska, 78000 Banja Luka, Bosnia and Herzegovina

25. Department for AIDS, Specialized Hospital for Active Treatment of Infectious and Parasitic Diseases—Sofia, Medical University Sofia, 1431 Sofia, Bulgaria

26. Department of AIDS, Epidemiology and Prevention, Central Research Institute of Epidemiology, Federal AIDS Centre, 111123 Moscow, Russia

27. HIV Out-Patient Clinic, Hospital for Infectious Diseases, Medical University of Warsaw, 01-201 Warsaw, Poland

Abstract

With no expected vaccine for HIV in the near future, we aimed to define the current situation and challenges for pre- and post-exposure prophylaxis (PrEP and PEP) in Central and Eastern Europe (CEE). The Euroguidelines CEE Network Group members were invited to respond to a 27-item survey including questions on PrEP (response rate 91.6%). PrEP was licensed in 68.2%; 95 centers offered PrEP and the estimated number on PrEP was around 9000. It was available in daily (40.1%), on-demand (13.3%), or both forms (33.3%). The access rate was <1–80%. Three major barriers for access were lack of knowledge/awareness among people who are in need (59.1%), not being reimbursed (50.0%), and low perception of HIV risk (45.5%). Non-occupational PEP was available in 86.4% and was recommended in the guidelines in 54.5%. It was fully reimbursed in 36.4%, only for accidental exposures in 40.9%, and was not reimbursed in 22.72%. Occupational PEP was available in 95.5% and was reimbursed fully. Although PrEP scale-up in the region has gained momentum, a huge gap exists between those who are in need of and those who can access PrEP. Prompt action is required to address the urgent need for PrEP scale-up in the CEE region.

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology

Reference54 articles.

1. (2022, November 12). Eastern Europe and Central Asia may Face an Accelerated Increase in New HIV Infections and AIDS-Related Deaths Because of the Humanitarian Crisis Gripping the Entire Region. UNAIDS. Available online: https://www.unaids.org/en/keywords/eastern-europe-and-central-asia#:~:text=According%20to%20the%20UNAIDS%20Global,a%2048%25%20increase%20since%202010.

2. European Centre for Disease Prevention and Control, WHO Regional Office for Europe (2022, November 12). HIV/AIDS Surveillance in Europe 2020–2019 Data. Stockholm: ECDC. Available online: https://www.ecdc.europa.eu/sites/default/files/documents/hiv-surveillance-report-2020.pdf.

3. European Centre for Disease Prevention and Control, WHO Regional Office for Europe (2022, December 15). HIV/AIDS Surveillance in Europe 2022–2021 Data. Copenhagen: WHO Regional Office for Europe. Available online: https://reliefweb.int/report/world/hivaids-surveillance-europe-2022–2021-data.

4. Reduced HIV Testing and Diagnoses During COVID-19 Pandemic;Kuehn;JAMA,2022

5. Skrzat-Klapaczynska, A., Kowalska, J.D., Afonina, L., Antonyak, S., Balayan, T., Begovac, J., Bursa, D., Dragovic, G., Gokengin, D., and Harxhi, A. (2022). The Management of HIV Care Services in Central and Eastern Europe: Data from the Euroguidelines in Central and Eastern Europe Network Group. Int. J. Environ. Res. Public Health, 19.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3